Diligence memo · auto-generated · as of July 2, 2026
Cellumen, Inc.
Cellumen, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cellumen, Inc. operates in Biotechnology, based in PITTSBURGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cellumen, Inc. has raised $1.6M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $694K on 2009-10-06.
Most recent recorded round closed around 2010-03-03.
Valuation (modeled)modeled
Provath models Cellumen, Inc. at approximately $14M (range $133K–$156M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.70× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era. Within the normal band (70% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 16.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 24% of Biotechnology peers (4293 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.